Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of Platelet Aggregability in Patients with Takayasu's Arteritis
Sponsor: Jose Carlos Nicolau
Summary
Inflammatory syndromes in general, and primary vasculitis specifically, present a high risk of cardiovascular involvement. Takayasu arteritis (TAK), for example, presents cardiovascular complications in up to 60% of cases. It is a systemic inflammatory disease that primarily affects large vessels, such as the aorta and its main branches. From a pathophysiological point of view, there are several causes that can lead to an exacerbated increase in cardiovascular risk in this population, including accelerated atherosclerosis, pro-inflammatory action of platelets and significant endothelial dysfunction. In this context, the present case-control study intends to include 100 individuals (50 with TAK - case group, and 50 healthy volunteers - control group), matched by age and sex in a 1:1 ratio. The main objective of the study is to compare platelet aggregability in patients with TAK against healthy volunteers using the AggRAM® test. Among its secondary objectives is the analysis of platelet aggregability by other methods (Plateletworks, Chronolog, and PPAnalysis). The study aims to significantly contribute to a better understanding of the potential influence of TAK on platelet aggregation and the response to antiplatelet agents, thereby contributing to a better understanding of the disease, with evident prognostic and therapeutic implications.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
100
Start Date
2024-10-14
Completion Date
2027-10-14
Last Updated
2025-02-04
Healthy Volunteers
Yes
Interventions
Clopidogrel
Clopidogrel 75 mg once a day for 14 days.
Locations (1)
Heart Institute (InCor) / University of São Paulo, São Paulo
São Paulo, São Paulo, Brazil